Original release date:
November 6, 2019
Access to this course expires on: September 19, 2022 at 11:59 PM Pacific Time
For the first time, the 2016 WHO classification of central nervous system (CNS) tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. These new updates will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors. General pathologists, in particular, must become familiar with changes in diagnostic criteria and utilize them in their practice improvement strategies. The WHO classification of pituitary adenomas was revised in 2017 and includes (1) a recommendation for the assessment of pituitary transcription factors with focus on adenohypophysial-cell lineage and (2) replacement of “atypical adenoma” with “high risk adenoma” based on tumor proliferation markers and other clinical parameters (such as invasion) to predict aggressiveness. This course will illustrate and reinforce these important updates.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
- Apply the cIMPACT-NOW and 2016 updates to the WHO classification for the diagnosis of adult diffuse gliomas
- Utilize morphologic and molecular diagnostic techniques to diagnose pediatric brain tumors
- Explain the role of integrated molecular and histological criteria in the classification of other CNS tumors including dural and embryonal neoplasms
- Summarize the changes in neuroendocrine and non-neuroendocrine pituitary tumor classification
- Apply the 2017 update to the WHO classification of pituitary tumors to the diagnosis of sellar region tumors
Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.5
AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 12.5 SAM/Part II credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Arie Perry, MD; Maria Beatriz S. Lopes, MD, PhD, Fausto J. Rodriguez, MD
The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Steven D. Billings, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME and SAM credit, all learners must complete the evaluation. View and print your certificate by
Buy the entire
Updates of the WHO Classification of Brain and Pituitary Tumors
course and get a great discount!
Not A Member?